Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen cash
Cash and short-term investments held at the end of each period.
Biogen's cash was $1.30B at Sep 30, 2026. For fiscal 2025 it was $3.82B, up 60.7% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $4.89B in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.82B | +60.7% |
| FY2024 | Dec 31, 2024 | $2.38B | +126.2% |
| FY2023 | Dec 31, 2023 | $1.05B | -78.5% |
| FY2022 | Dec 31, 2022 | $4.89B | +28.7% |
| FY2021 | Dec 31, 2021 | $3.80B | +45.7% |
| FY2020 | Dec 31, 2020 | $2.61B | -41.7% |
| FY2019 | Dec 31, 2019 | $4.48B | +26.5% |
| FY2018 | Dec 31, 2018 | $3.54B | -4.1% |
| FY2017 | Dec 31, 2017 | $3.69B | +58.6% |
| FY2016 | Dec 31, 2016 | $2.33B | +77.9% |
| FY2015 | Dec 31, 2015 | $1.31B | +8.6% |
| FY2014 | Dec 31, 2014 | $1.20B | +100.0% |
| FY2013 | Dec 31, 2013 | $602.60M | -64.7% |
| FY2012 | Dec 31, 2012 | $1.71B | +0.9% |
| FY2011 | Dec 31, 2011 | $1.69B | +40.0% |
| FY2010 | Dec 31, 2010 | $1.21B | -4.4% |
| FY2009 | Dec 31, 2009 | $1.26B | -5.8% |
| FY2008 | Dec 31, 2008 | $1.34B | +103.4% |
| FY2007 | Dec 31, 2007 | $659.66M | -0.3% |
| FY2006 | Dec 31, 2006 | $661.38M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.30B | -67.1% |
| Q2 FY2026 | Jun 30, 2026 | $1.29B | -53.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.28B | +64.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.82B | +60.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.96B | +133.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.76B | +44.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.60B | +141.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.38B | +126.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.70B | -25.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.91B | -68.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.07B | -78.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.05B | -78.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.29B | -53.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.08B | +26.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.04B | +34.4% |
| Q4 FY2022 | Dec 31, 2022 | $4.89B | +28.7% |
| Q3 FY2022 | Sep 30, 2022 | $4.91B | +66.2% |
| Q2 FY2022 | Jun 30, 2022 | $4.80B | +57.3% |
| Q1 FY2022 | Mar 31, 2022 | $3.75B | +47.9% |
| Q4 FY2021 | Dec 31, 2021 | $3.80B | +45.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.96B | -17.5% |
| Q2 FY2021 | Jun 30, 2021 | $3.05B | -29.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.54B | -34.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.61B | -41.7% |
| Q3 FY2020 | Sep 30, 2020 | $3.58B | -19.3% |
| Q2 FY2020 | Jun 30, 2020 | $4.33B | +46.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.86B | -1.2% |
| Q4 FY2019 | Dec 31, 2019 | $4.48B | +26.5% |
| Q3 FY2019 | Sep 30, 2019 | $4.44B | +0.2% |
| Q2 FY2019 | Jun 30, 2019 | $2.95B | -8.4% |
| Q1 FY2019 | Mar 31, 2019 | $3.91B | -4.8% |
| Q4 FY2018 | Dec 31, 2018 | $3.54B | -4.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.43B | +186.1% |
| Q2 FY2018 | Jun 30, 2018 | $3.22B | +175.7% |
| Q1 FY2018 | Mar 31, 2018 | $4.11B | +344.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.69B | +58.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.55B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.17B | – |
| Q1 FY2017 | Mar 31, 2017 | $924.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.33B | – |
See a number that looks wrong?